Ranbaxy Laboratories will have to pay a Rs 242 crore fine to the US authorities due to violations found at its Active Pharmaceutical Ingredient (API) manufacturing factory in Toansa, Punjab, sources, in the know told Business Standard.
The facility is currently banned from supplying products to the American market. An email query sent to Ranbaxy did not elicit any response.
ALSO READ: US FDA differs with EU on Ranbaxy plant safety
This will be the second such hefty penalty for the company, which paid $ 500 million to the US department of justice (DoJ) in May 2013, after it pleaded guilty to felony charges related to drug safety and misrepresenting data to gain faster approvals. This comprised $ 150 mn for a criminal charge and forfeiture and $ 350 mn in payments for civil claims.
According to a source, the latest penalty has also been imposed by the DoJ and is specifically related to the violations found at Toansa. Earlier this year, the unit was issued an administrative summons by the US attorney for the district of New Jersey. Sources said this was triggered through an investigation into alleged fraud and violation of manufacturing norms. The company was asked to produce certain documents relating to issues previously raised by the FDA with respect to the Toansa facility.
ALSO READ: No sabotage at Toansa plant, says Ranbaxy
In January, the US Food and Drug Administration (US FDA) had barred supplies from the API plant to America. This was after inspecting authorities found severe lapses in norms and procedures, including presence of flies in the sample storage room, un-calibrated instruments in the laboratory and non-adherence to sample analysis procedures.
The Ranbaxy management said it had initiated a third-party investigation to find the guilty, following the US FDA enforcement on the Toansa factory.
Currently, all four factories of Ranbaxy in India, at Poanta Sahib (Himachal), Dewas (Madhya Pradesh), Mohali (Punjab) and Toansa are all barred from supplying products to the US market. All these plants are also part of an ongoing consent decree signed by the company to take corrective measures, as prescribed by the regulator.
“The financial penalty is set to go up as the number of plants under the decree increases,” one of the sources said.
ALSO READ: Flies found in Toansa plant of Ranbaxy’s storage room: FDA
The latest penalty is likely to have a significant impact on Ranbaxy’s financials, already under pressure following the US ban on its domestic manufacturing facilities. Consolidated sales in April-June were Rs 2,372 crore, as against Rs 2,584 crore in the corresponding period a year before. Sales from the North American market dipped 11 per cent over a year to Rs 760 crore. Of this, the US market contributed Rs 700 crore.
During the April-June quarter, the Gurgaon headquartered drug maker, which is in the process of being acquired by its domestic rival Sun Pharmaceutical Industries, had also made a provisioning of around Rs 237.8 crore for a possible settlement with the US government. However, the company did not reveal the nature of the settlement.
“We are not disclosing details as of now… It is a provision and as soon as the settlement is done, we will be in a position to disclose more,” Ranbaxy chief financial officer Indrajit Banerjee had told analysts in a post-earnings conference call.
On Thursday, shares of Ranbaxy Laboratories ended at Rs 641.10 on the Bombay Stock Exchange, up 1.83 per cent from their previous close.